BioPharma Credit PLC

BioPharma Credit PLC
Pharmakon Advisors L.P.
Closed Ended Investment Company
Debt - Direct Lending
1.56 %
7.6 %
Fund Size
£ 1.37 billion
Discount Premium
The company will seek to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The company will seek to achieve its investment objective predominantly through direct or indirect exposure to Debt Assets. The Company may also invest in equity issued by a LifeSci Company, acquired directly from the LifeSci Company; or in the secondary market.
Holding %
Tesaro Senior Secured Loan2024 23.99 %
Lexicon Senior Secured Loan2022 13.45 %
Senior Secured Loan2020 4.99 %
Senior Secured Loan2022 4.71 %
Senior Secured Loan2021 1.50 %
Senior Secured Loan2018 1.38 %
Pharmakon Advisors L.P.
10022, New York, United States
Legal Structure
Closed Ended Investment Company


Pedro Gonzalez de Cosio
Joined 03/27/2017

Mr. Gonzalez de Cosio is a Principal and co-founder of the Investment Manager and will manage the Company’s portfolio. During the 14 years prior to founding the Investment Manager, Mr. Gonzalez de Cosio held various positions in the structured finance divisions of Deutsche Bank and JP Morgan in New York, where he was responsible for structuring various forms of collateralised financings and derivatives for US and international clients, including several years covering clients in the life sciences industries. Mr. Gonzalez de Cosio’s prior experience also includes various positions in the investment banking division of Nomura Securities in New York, the leasing division of Socie´te´ Ge´ne´rale in Paris, and coordinating the issuance of external debt for the Mexican Ministry of Finance. Mr. Gonzalez de Cosio earned a B.A. degree (Summa Cum Laude) in Business Administration from the University of San Diego and an M.B.A. from INSEAD in Fontainebleau, France.

Pablo Legorreta
Joined 03/27/2017

Mr. Legorreta is co-founder and Chief Executive Officer of Royalty Pharma and a Principal and cofounder of the Investment Manager providing advisory oversight. Royalty Pharma was founded in 1996 and is a premier investor in pharmaceutical royalties. Prior to founding Royalty Pharma, Mr. Legorreta had a 10 year career in investment banking with Lazard Fre`res in Paris and New York. During his tenure at Lazard Fre`res, Mr. Legorreta co-founded two ‘‘proof of principle’’ funds that acquired royalties in Neupogen in 1993 and ReoPro in 1994. Mr. Legorreta is also a Director of Giuliani S.p.A. Mr. Legorreta is a member of the Association of University Technology Managers, the Licensing Executives Society, the Swiss Pharmaceutical Group, the Biotechnology Industry Organization, the Children’s Circle of Care and is a founding member of the Research Council of Boston’s Children’s Hospital. Mr. Legorreta earned a degree in Industrial Engineering from Universidad Iberoamericana in Mexico City, Mexico.

Martin Friedman
Joined 03/27/2017

Mr. Friedman is a Principal of the Investment Manager, having joined in 2011. Mr. Friedman has spent the past 22 years in various positions in the healthcare finance industry, most recently as the co-head of the US life sciences banking at Bank of America/Merill Lynch. He has worked very closely with both large cap and emerging pharmaceutical, biotech, specialty pharmaceutical, device and diagnostic companies, having advised on M&A transactions and raised equity and debt capital. Mr. Friedman’s prior experience also includes his 12 years at JPMorgan, including four years at JPMorgan Partners, and several years as the Head of M&A and Collaborations at Novartis AG based in Switzerland. Mr. Friedman earned a B.A. degree in English and History from Columbia College and an M.B.A. (Honours) in Finance and Accounting from Columbia Business School.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.